Abstract

Research Article

Pattern of LRR in Endometrial Cancer and Identification of Predictive Factors

Alia Mousli, Mohamed Aziz Cherif*, Marouen Benna, Ameni Yousfi, Semia Zaraa, Rim Abidi and Chiraz Nasr

Published: 08 July, 2024 | Volume 7 - Issue 3 | Pages: 078-083

Background: Tailored adjuvant treatment is key to managing endometrial cancer effectively. Understanding prognostic factors of loco-regional failure and the impact of adjuvant treatment can help in treatment de-escalation without compromising survival outcomes.
The aim of this study was to assess the pattern of failure in endometrial cancer patients and to determine predicting Loco-Regional Recurrence (LRR) factors.
Patients and methods: Data were collected from 214 patients treated for endometrial cancer between 2005 and 2012 in Salah Azaiez Institute in Tunisia. All patients underwent upfront surgery followed by adjuvant brachytherapy with or without external beam radiation. The median follow-up period was 44 months. Univariate and multivariate analyses were performed to identify prognostic factors for LRR.
Results: The 5-year overall survival rate was 78.1%, and the 5-year progression-free survival rate was 80.1%. LRR occurred in 25 patients (11.6%), with a median recurrence time of 29 months (range 4 months - 46 months). Pelvic relapse was the most common site, occurring in 10 patients. Vaginal relapses were observed in 9 patients, and retro-peritoneal relapses were observed in 6 cases. FIGO stage, tumor grade, histologic type, Lympho-Vascular Space Invasion (LVSI), and delays in adjuvant treatment were significant predictors of LRR.
Conclusion: Identifying prognostic factors for LRR in endometrial cancer is crucial for optimizing adjuvant treatment strategies. Higher FIGO stages and the presence of LVSI were independent predictive factors for LRR. Tailored adjuvant treatment, taking these prognostic factors into account, is essential to improve patient outcomes and minimize unnecessary treatment-related toxicity.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001169 Cite this Article Read Full Article PDF

Keywords:

Endometrial cancer; Loco-regional recurrence; Predictive factors; FIGO stage; Lympho-vascular space invasion; Adjuvant treatment

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. Erratum in: CA Cancer J Clin. 2005 Jul-Aug;55(4):259. Available from: https://doi.org/10.3322/canjclin.55.1.10
  2. Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T; Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006 Jun;101(3):520-529. Available from: https://doi.org/10.1016/j.ygyno.2006.02.011
  3. Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011 Mar 31;22(1):3-8. Available from: https://doi.org/10.3802/jgo.2011.22.1.3
  4. Turan T, Ureyen I, Karalok A, Tasci T, Turkmen O, Kocak O, et al. Pulmonary recurrence in patients with endometrial cancer. J Chin Med Assoc. 2016 Apr;79(4):212-220. Available from: https://doi.org/10.1016/j.jcma.2015.10.010
  5. Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol. 1991 Jul;78(1):63-69. Available from: https://pubmed.ncbi.nlm.nih.gov/2047070/
  6. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002 Mar;84(3):437-442. doi: 10.1006/gyno.2001.6550. PMID: 11855884. Available from: https://doi.org/10.1006/gyno.2001.6550
  7. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009 May;105(2):103-104. doi: 10.1016/j.ijgo.2009.02.012. Erratum in: Int J Gynaecol Obstet. 2010 Feb;108(2):176. Available from: https://doi.org/10.1016/j.ijgo.2009.02.012
  8. Sartori E, Laface B, Gadducci A, Maggino T, Zola P, Landoni F, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003 Jul-Aug;13(4):458-465. Available from: https://pubmed.ncbi.nlm.nih.gov/12911722/
  9. Barlin JN, Zhou Q, St Clair CM, Iasonos A, Soslow RA, Alektiar KM, et al. Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecol Oncol. 2013 Sep;130(3):452-456. Available from: https://doi.org/10.1016/j.ygyno.2013.06.009
  10. Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):530-539. Available from: https://doi.org/10.1016/j.ijrobp.2014.11.022
  11. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-751. Available from: https://doi.org/10.1016/j.ygyno.2003.11.048
  12. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012 Nov 7;104(21):1625-1634. doi: 10.1093/jnci/djs374. Epub 2012 Sep 6. PMID: 22962693. Available from: https://doi.org/10.1093/jnci/djs374
  13. Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique. National Cancer Institute; French Society of Gynecological Oncology. Int J Gynecol Cancer. 2011 Jul;21(5):945-950. Available from: https://doi.org/10.1097/IGC.0b013e31821bd473
  14. Briët JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005 Mar;96(3):799-804. Available from: https://doi.org/10.1016/j.ygyno.2004.11.033
  15. Gadducci A, Cavazzana A, Cosio S, DI Cristofano C, Tana R, Fanucchi A, et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res. 2009 May;29(5):1715-1720. PMID: 19443392. Available from: https://pubmed.ncbi.nlm.nih.gov/19443392/
  16. Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012 Jan;124(1):31-35. Available from: https://doi.org/10.1016/j.ygyno.2011.09.017
  17. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016 Jan;26(1):2-30. Available from: https://doi.org/10.1097/IGC.0000000000000609
  18. Elliott P, Green D, Coates A, Krieger M, Russell P, Coppleson M, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 1994 Mar;4(2):84-93. Available from: https://doi.org/10.1046/j.1525-1438.1994.04020084.x
  19. Albertini AF, Devouassoux-Shisheboran M, Genestie C. Pathology of endometrioid carcinoma. Bull Cancer. 2012 Jan;99(1):7-12. Available from: https://doi.org/10.1684/bdc.2011.1526
  20. Hentati D, Belghith B, Kochbati L, Driss M, Maalej M. Clear cell carcinoma of the uterus. Tunis Med. 2010 Apr;88(4):230-233. Available from: https://pubmed.ncbi.nlm.nih.gov/20446254/
  21. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ. Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol. 2012 May;23(5):1178-1184. Available from: https://doi.org/10.1093/annonc/mdr368
  22. Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, et al. DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium. Virchows Arch. 2012 Sep;461(3):291-298. Available from: https://doi.org/10.1007/s00428-012-1275-2
  23. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013 Aug 7;105(15):1142-1150. Available from: https://doi.org/10.1093/jnci/djt144
  24. Sorbe B. Predictive and prognostic factors in definition of risk groups in endometrial carcinoma. ISRN Obstet Gynecol. 2012;2012:325790. Available from: https://pubmed.ncbi.nlm.nih.gov/23209924/
  25. Ouh YT, Oh Y, Joo J, Woo JH, Han HJ, Cho HW, et al. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence. Cancers (Basel). 2024 Feb 27;16(5):965. Available from: https://doi.org/10.3390/cancers16050965
  26. León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. TransPORTEC consortium. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020 Oct 10;38(29):3388-3397. Available from: https://doi.org/10.1200/JCO.20.00549
  27. van den Heerik ASVM, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021 Apr;31(4):594-604. Available from: https://doi.org/10.1136/ijgc-2020-001822

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?